Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease

Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease; a Pilot Study

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03227822

Acronym

STRONG

Enrollment

Registered

2017-07-24

Start date

2013-07-31

Completion date

2015-02-01

Last updated

2018-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Arterial Disease

Brief summary

Since the length of lesion seems to be negatively associated with stent patency due to restenosis, it is thought that the efficacy of treatment in patients with multiple (\> 1) short (focal; \> 1 and \< 5 cm) SFA lesions can be improved by spot stenting as compared to the use of one long stent. This study proposes to evaluate the endovascular treatment for patients with SFA lesions by comparing two strategies for patients with extensive occlusive SFA disease; 1) short spot (SS) stenting or 2) long lesion (LL) stenting.

Interventions

PROCEDUREShort spot stenting

PROCEDURELong lesion stenting

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* PAOD (ABI \<0.90 and/or a decline of \>0.15 after exercise test), Rutherford category 2, 3 or 4 * Multiple (\>1) short (focal; \>1 and \< 5 cm) significant stenoses (≥ 50%) and/or occlusions in the superficial femoral artery * Eligible for endovascular treatment via short spot stenting and via long lesion stenting according to international guidelines * Unilateral occlusive disease * Age ≥ 18

Exclusion criteria

* Patients with PAOD Rutherford category 5 and 6 * Impaired inflow due to significant lesions in the arteries proximal to the SFA intended to treat * Bilateral lesions with treatment indication * Contra-indication for anticoagulant therapy * Renal insufficiency (MDRD \< 50 ml/min) * Life expectancy \< 6 months * Known contrast allergy * Pregnancy * Unable to complete a questionnaire in the home language

Design outcomes

Primary

Measure	Time frame
absence of binary restenosis (≥ 50% re-obstruction) of the target lesion without interval clinically driven reintervention	1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026